Filter News

Bioject Medical Technologies Inc. To Report Second Quarter 2006 Financial Results

Published: Jul 28, 2006

PORTLAND, Ore., July 27 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, announced today that the Company will report its financial results for the second quarter ended June 30, 2006 on Wednesday, August 2, 2006, after the close of the financial markets. Management will conduct a conference call on Thursday, August 3, 2006, at 10:00 a.m. Eastern Time to review the results for the quarter and the year. Jim O'Shea, Chairman, President, and CEO, and Chris Farrell, Vice President of Finance will be hosting the call.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public. To participate in the call via telephone, please dial 1-877-407-8037, or to access the call live over the Internet, visit Bioject's website at www.bioject.com and click on the Investor Relations section, then on the event icon. A conference call replay will also be available until August 11, 2006. To listen to the replay, please dial 1-877-660-6853 replay account number 7303, identification number 210178.

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information about Bioject, visit: www.bioject.com.

Bioject Medical Technologies Inc.

CONTACT: Jim O'Shea, Chief Executive Officer, +1-503-692-8001, ext. 4161,or Chris Farrell, Vice President of Finance, +1-503-692-8001, ext. 4132,both of Bioject Medical Technologies Inc.

Back to news